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Abstract
Background: The majority of patients with prostate cancer (International Classification of Diseases, 10th edition,
code C61) are elderly. With Japan’s rapidly society aging, both the prevalence and mortality of prostate cancer are
expected to increase in the future. The objective of this study was to estimate and predict the cost of illness (COI)
associated with prostate cancer in Japan.
Methods: Using a COI method based on available data from government office statistics, we estimated the COI for
2002, 2005, 2008, and 2011. We then predicted the COI for 2014, 2017, and 2020 using fixed model estimation and
variable model estimation. With fixed model estimation, only estimated future population was used as a variable.
Variable model estimation considered the time trend of health-related indicators in the past 15 years. We derived
the COI from the sum of direct and indirect costs (morbidity and mortality).
Results: We found the predicted future COI of prostate cancer to be 354.7–378.3 billion yen in 2014, 370.8–421.0
billion yen in 2017, and 385.3–474.1 billion yen in 2020. Regardless of the estimation model, we found that COI
would increase compared with the baseline year 2011 (307.3 billion yen). The direct costs for inpatient and
outpatient treatment, laboratory tests, and drugs accounted for 60–75 % of the COI of prostate cancer.
Conclusions: The results of this study suggest that the COI of prostate cancer in Japan has steadily increased and
is expected to rise in the future. Direct costs comprised the largest proportion of the COI and are anticipated to
continue expanding; this will result in increased burden on public funds in Japan, where a universal public
insurance system operates. These trends differ from those with other forms of cancer.
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Background
Prostate cancer is one of the most common cancers in
men, particularly in the United States, Canada, and
Europe. The prevalence and incidence of prostate cancer
varies across countries [1, 2]. In recent years, patient num-
bers and mortality rates for prostate cancer (International
Classification of Diseases, 10th edition, code C61) have in-
creased in Japan. Prostate cancer is the seventh-leading
cause of cancer death in Japanese men. The majority of
prostate cancer cases involve the elderly. According to the
governmental Patient Survey [3], 60.8 % of prostate cancer
patients were 75 years or older; this compares with 42.3 %
for lung cancer and 37.5 % for stomach cancer. The aver-
age age of death from prostate cancer in Japan in 2008
was 78.8 years, which was higher than with other cancers,
such as lung (74.1 years) and stomach cancer (74.4 years).
As Japan’s elderly population continues to grow, the
prevalence and mortality of prostate cancer are expected
to increase proportionately.
Age-standardized incidence of prostate cancer is high
in the United States and Canada [4]. Studies that have
attempted to clarify the social burden of prostate cancer
have also been conducted in those countries [5]. Roehr-
born et al. [6] researched the cost of prostate cancer in
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several countries, including the United States. They sug-
gested that despite declining mortality rates, the social
burden of prostate cancer in the United States would
continue to increase owing to a greater number of pa-
tients being diagnosed and treated at an earlier stage.
Medical expenses for the treatment of prostate cancer in
Canada were estimated from a social perspective [7]. It
was found that the direct health-care costs of treating
over 700,000 cases of prostate cancer among Canadian
men aged 40–80 years in 1997 would amount to C$9.76
billion. The social burden of prostate cancer—including
productivity loss from premature death and the many
costs associated with morbidity—have been fully investi-
gated [8]. To determine the social burden of prostate
cancer in Japan, assessments based on the Survey of
Medical Care Activities in Public Health Insurance and
the Patient Survey have been conducted [9]; however,
most of those were snapshot estimations that did not
consider demographic dynamics, such as Japan’s rapidly
aging population.
A comprehensive economic analysis demands a con-
sideration of both direct and indirect costs; the latter in-
clude productivity losses as a result of individuals unable
to work because of hospitalization or outpatient visits,
as well as premature death resulting from the illness.
The cost of illness (COI) method developed by Rice and
co-workers [10, 11], which evaluates financial losses as a
result of illness in a prescribed statistical universe, has
been widely used to estimate the social burden of dis-
ease. The COI can be used as a criterion for decision
making in allocating limited budgets and resources for
governmental health policies in disease control. By ap-
plying this approach with diseases, it is possible to com-
pare and set priorities in policy making for the
simultaneous management of several major diseases.
The purpose of this study was to estimate and predict
the economic burden associated with prostate cancer in
Japan compared with other cancers.
Methods
We used the COI method to examine the economic bur-
den of prostate cancer. Calculation method employed in
this study which used government office statistics and
the COI method was same as our previous study [12].
First, we calculated COI of 2002, 2005, 2008, and 2011.
We then predicted the future COI [13] based on those
results. We adapted top-down approach of COI method
aggregating published national surveys and based on
prevalence of prostate cancer.
Data sources
We used the government office statistics listed below. The
survey results of the Central Social Insurance Medical
Council were employed to determine the hospitalization
cost per day of prostate cancer. The Survey of Medical
Care Activities in Public Health Insurance was used to
examine outpatient cost per day. We used the Basic
Survey on Wage Structure, Labour Force Survey, and Esti-
mates of Monetary Valuation of Unpaid Work to calculate
labour value. We employed Vital Statistics to evaluate the
number of deaths caused by prostate cancer. The Patient
Survey was used to identify the number of patients, total
person-days of outpatient visits, and average length of stay
for prostate cancer. Population Projections for Japan re-
leased by the National Institute of Population and Social
Security Research in Japan were used to refer future
population.
Measurement and valuation
Components of COI were shown in Table 1. The COI
comprises direct cost (DC) and indirect cost (IC). IC in-
cludes morbidity cost (MbC) and mortality cost (MtC).
COI is calculated using the following equation:
COI ¼ DCþMbCþMtC:
The DC comprises hospitalization cost (HC) and out-
patient cost (OC) and it is calculated using the following
equation:
DC ¼ HCþOC ¼ iCd THDþ oCd TOVy:
The HC was determined by multiplying the inpatient cost
per day (iCd) for prostate cancer and total person-days of
hospitalization (THD). The OC was determined by multi-
plying the OC per day (oCd) for all cancers and the total
person-days of outpatient visits (TOVy) for prostate cancer.
All inpatients were assumed to undergo an operation,
but the cost of radiotherapy was not included. Because
data were available only for 2005, iCd of 2005 (48,844
yen) was used as the baseline. The iCd of prostate can-
cer was calculated assuming the rate of change of iCd
for prostate cancer to be the same as that of iCd for all
cancers. The iCd for each year was calculated by multi-
plying the rate of change and the value for 2005. Watch-
ful waiting is one of the major treatments in Japan.
Patients who underwent watchful waiting were included
in TOVy. The oCd was 19,731 yen in 2011.
MbC comprised the MbC of inpatients (MbCi) and
outpatients (MbCo). MbCi was calculated by multiplying
1-day labour value per person (LVd) and the THD ac-
cording to sex and 5-year age groups. MbCo was deter-
mined by multiplying the half of LVd and TOVy
according to sex and 5-year age groups.
MtC was measured as the loss of human capital (hu-
man capital method), which was calculated by multiply-
ing the number of deaths (NDy) and the lifetime labour
value per person (LVl). LVl was determined by summing
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the patients’ potential income, which would have ac-
crued in the future had they not died, from the age of
death to life expectancy. MbC and MtC were calculated
using the following equations:
MbC ¼MbCiþMbCo
¼ THD LVdþ TOVy  LVd=2:
MtC ¼ NDy  LVl:
Pensions were not included in MbC and MtC. Future
labour value was adjusted to a present value using a 3 %
discount rate.
Statistical approach
To examine changes over time, we first estimated the
COIs for 2002, 2005, 2008, and 2011 using available
data. Next, to make future predictions, we estimated the
COIs for 2014, 2017, and 2020 using the two methods
described below. The Patient Survey is conducted every
3 years in Japan. We calculated the COI to match the
year of the Patient Survey.
Estimates of future COI were made using two methods
[13]—fixed model estimation and variable model estima-
tion. Variable model estimation consisted of a linear
model, logarithmic model, and mixed model depending
on which formula was selected for the health-related
indicators.
Fixed model is the estimation that assumed health-
related indicator (such as mortality rate, number of out-
patient visits, and average length of stay) were fixed and
it unrelated to the time trend of health-related indica-
tors. We used those values at 2011, and only future
population estimation was used as a variable. With fixed
model estimation, we first calculated the mortality rate,
number of outpatient visits per population, and number
of hospitalizations per population according to sex and
5-year age groups in 2011 as standard year indicators.
Next, by multiplying these factors with future population
estimates according to sex and 5-year age groups for
2014, 2017, and 2020, we calculated the predictive num-
ber of deaths, TOVy, and THD. We estimated MbC and
MtC for 2014, 2017, and 2020 using the 2011 data for
average length of stay, life expectancy, labour value, iCd,
and outpatient visits.
With variable model estimation, we drew a trend line for
each health-related indicator by using a logarithmic or lin-
ear approximation with six time points referencing 1996,
1999, 2002, 2005, 2008, and 2011. We then extended the
Table 1 Components of COI
Components of COI Formulas / Data sources
COI Cost of illness DC +MbC +MtC
DC Direct cost HC + OC
HC Hospitalization cost iCd × THD
iCd Inpatient cost per day Survey results of the Central Social Insurance Medical Council
THD Total person-days of
hospitalization
Patient Survey
OC Outpatient cost oCd × TOVy
oCd Outpatient cost per day Survey of Medical Care Activities in Public Health Insurance
TOVy Total person-days of
outpatient visits
Patient Survey
MbC Morbidity cost MbCi + MbCo
MbCi Morbidity cost of inpatients THD × LVd
THD Total person-days of
hospitalization
Patient Survey
LVd 1-day labour value per person Basic Survey on Wage Structure, Labour Force Survey, Estimates
of Monetary Valuation of Unpaid Work
MbCo Morbidity cost of outpatients TOVy × LVd/2
TOVy Total person-days of
outpatient visits
Patient Survey
LVd/2 1/2-day labour value per
person
Basic Survey on Wage Structure, Labour Force Survey, Estimates
of Monetary Valuation of Unpaid Work
MtC Mortality cost NDy × LVl
NDy Number of deaths Vital Statistics
LVl Lifetime labour value per
person
Basic Survey on Wage Structure, Labour Force Survey, Estimates
of Monetary Valuation of Unpaid Work, Life table
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trend line for each approximation to determine values for
2014, 2017, and 2020. Variable models assumed every
health-related indicator as a variable. Indicators had their
own trend line. Difference of time trend among indicators
was reflected in calculation process by variables. This is the
reason why it was named variable model estimation for this
approach.
The estimated future health-related indicators were
used in addition to future population estimates. Because
the trend of each health-related indicator was different,
the single model estimation (logarithm model and linear
model) might not predict future COI precisely. There-
fore, we developed a mixed model, which adopted the
value with a higher coefficient of determination for each
5-year age groups [13]. Our mixed model was an ap-
proximation using health-related indicators with a
higher coefficient of determination in a logarithmic and
linear approximation for each 5-year age groups. By
mixing the optimal results of both logarithmic and linear
model depending on the characteristics of each health-
related indicator, getting more appropriate estimates
could be possible. This is the reason why it was named
mixed model for this approach. This method was already
employed in our previous study [13]. Because the mixed
model was a combination of models with a higher coeffi-
cient of determination, we believed the mixed model to
be the most valid for this study. The fixed model was
the simplest method and could be regarded as a refer-
ence. The estimations using the logarithmic and linear
models can be regarded as a sensitivity analysis to test
the robustness of the mixed model.
When estimating using the trend line, a future pre-
dicted value sometimes took less than 0. They are un-
likely to reflect actual conditions. Therefore, we needed
to set a “minimum value”. For mortality rate, number of
times of outpatient visit per population and number of
times of hospitalization per population, the minimum
value was set as the value from the year prior to that in
which the estimate was less than 0. In this study, we as-
sumed that the value from the year prior to that when
the estimate was less than 0 would be maintained there-
after. Negative value was not used in this model. As for
average length of stay, we set 8.1 days the average length
of stay of patients with prostate cancer (2012) of 28
Organization for Economic Co-operation and Develop-
ment (OECD) countries - as “minimum value”.
The current study used only anonymous governmental
data; no human or animal subjects were involved. No in-
stitutional review is required for this type of research in
Japan [14].
Results
Estimates of health-related indicators
In conceiving this study, we expected that the number of
deaths would increase across all models. With a reference
value of 1.00 for 2011, we found that the values would in-
crease as follows: to 1.15 (fixed model) and 1.20 (logarith-
mic model) in 2014; 1.27 (fixed model) and 1.33
(logarithmic model) in 2017; and 1.37 (fixed model) and
1.44 (logarithmic model) in 2020.
We found that the number of outpatients would also
increase proportionately. With a reference value of 1.00
in 2011, the values would increase as follows: to 1.09
(fixed model) and 1.36 (linear model) in 2014; 1.10 (fixed
model) and 1.55 (linear model) in 2017; and 1.20 (fixed
model) and 1.80 (linear model) in 2020. The total num-
ber of times of hospitalization and THD would also in-
crease (Table 2).
We found that the average age of death rose from
77.9 years (2002) to 79.3 years (2011). This trend would
Table 2 Projected results of health-related indicators of prostate cancer*
2011 (base line) Future estimates
2014 2017 2020
Number of prostate cancer death (person) Fixed model 12,425 (1.15) 13,726 (1.27) 14,833 (1.37)
10,823 (1.00) Linear model 12,862 (1.19) 14,165 (1.31) 15,352 (1.42)
Logarithmic model 12,934 (1.20) 14,341 (1.33) 15,597 (1.44)
Number of outpatient visit (person) Fixed model 5,585,678 (1.09) 5,655,557 (1.10) 6,176,422 (1.20)
5,139,223 (1.00) Linear model 6,979,937 (1.36) 7,987,933 (1.55) 9,254,791 (1.80)
Logarithmic model 5,696,500 (1.11) 6,154,510 (1.20) 6,747,682 (1.31)
Number of times of hospitalization (times) Fixed model 15,061 (1.05) 15,489 (1.08) 15,911 (1.11)
14,300 (1.00) Linear model 17,981 (1.26) 20,439 (1.43) 23,251 (1.63)
Logarithmic model 15,673 (1.10) 16,822 (1.18) 18,155 (1.27)
Total days of hospitalization (days) Fixed model 1,938,841 (1.10) 2,069,475 (1.18) 2,178,139 (1.24)
1,756,560 (1.00) Linear model 1,769,365 (1.01) 2,011,227 (1.14) 2,287,945 (1.30)
Logarithmic model 1,895,770 (1.08) 1,884,734 (1.07) 1,869,085 (1.06)
*Index number having a value of 1.00 at baseline shown in parentheses
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continue in the future, rising as follows: to 79.9 years
(fixed model) and 80.3 years (logarithmic model) in 2014;
80.4 years (fixed model) and 80.8 years (linear model) in
2017; and 80.7 years (fixed model) to 81.3 years (linear
model) in 2020. The estimated average age of death in
2014 with the logarithmic model was higher than with the
linear model. However, the estimated average age of death
in 2017 and 2020 with the linear model was higher than
with the logarithmic model. The linear model displayed a
higher slope between 2014 and 2020 than the logarithmic
model (Table 3). The value of the average length of stay in
2020 estimated using the linear model was less than 0.
Estimates of COI
The estimated COI of prostate cancer was 174.5 billion
yen in 2002, 246.9 billion yen in 2005, 286.0 billion yen
in 2008, and 307.3 billion yen in 2011. The future esti-
mates for the COI appear in Table 4. The health-related
indicators used for the future estimates are presented in
Table 2. The COI would increase as follows: to 354.7 bil-
lion yen (fixed model) and 378.3 billion yen (linear
model) in 2014; 370.8 billion yen (logarithmic model)
and 421.0 billion yen (linear model) in 2017; and 385.3
billion yen (logarithmic model) and 474.1 billion yen
(linear model) in 2020. With the mixed model, a loga-
rithmic approximation was used for the average length
of stay and a linear approximation was also employed
for the number of outpatient visits, hospitalizations per
population, and mortality. With the mixed model, the
COI was estimated to increase from 362.0 billion yen in
2011 to 451.9 billion yen in 2020—a 1.5-fold increase.
DC was the largest component of the COI, account-
ing for 55.6 % in 2002 and 71.4 % in 2011. With the
mixed model, DC was expected to increase to 74.4 %
in 2020. However, the mixed model predicted that the
proportion of MtC would decrease from 22.8 % in
2011 to 18.5 % in 2020.
Discussion
The COI of prostate cancer in Japan is expected to con-
tinue increasing. This study found that this trend will
continue until at least 2020 and that DC will also stead-
ily rise well into the future.
Because most prostate cancer patients are elderly, the
COI of prostate cancer may differ from that with other
cancers. Our previous study suggested that, in Japan,
MtC accounted for 60–80 % of the COI in other forms
of cancer, such as that of the stomach, colon, rectum,
liver, lung, breast, uterus, malignant lymphoma, and
leukaemia [12]. With prostate cancer, the MtC ranged
from 25 to 38 %. The DC of the above-mentioned can-
cers accounted for 12–19 % of the COI; it was 56–69 %
in prostate cancer. Such differences were owing to the
average patient age and average age of death from pros-
tate cancer being higher than those with other cancers.
These differences have an effect on the time trend with
the COI. Our previous study of the COI of stomach can-
cer in Japan [13] established that this COI exhibited a
downward trend from 1996 to 2008 and that this would
continue until 2020; this is thus the reverse of the trend
with prostate cancer.
The human capital method evaluates the labour value of
the elderly as low compared with that of younger people.
Therefore, the opportunity cost of the elderly, which
reflects hospitalization and outpatient visits as well as esti-
mated income that patients might have earned during
their working years, is projected to be lower than in youn-
ger people. The average age of death from cancers other
than prostate was found to be 64.9–75.1 years [12]
compared with 78.8 years for prostate cancer in 2008. Ac-
cording to our mixed model estimates, MtC increases
were statistically lower than the rise in mortality. There-
fore, the influence of increased MtC associated with the
growing number of deaths from prostate cancer would be
negligible in future valuations of the COI.
The tendency of a higher average age of prostate cancer
patients and a higher average age of death will continue in
the future; the proportion of mortality and morbidity costs
in the COI of prostate cancer will remain low compared
with that for other cancers. In countries such as Japan where
public funds are used in medical insurance systems, an in-
crease in the DC over time signifies that the public sector
will continue to be burdened by expanding health-care
costs. When evaluating the allocation of resources for cancer
control in the future, it is necessary to consider differences
in the characteristics among the different forms of cancer.
Several related studies on the social burden of prostate
cancer have been published. Koinuma [9] reported that
the cost of prostate cancer in Japan amounted to 270.9 bil-
lion yen in 2005; this result is similar to that in the present
study (246.9 billion yen in 2005). His estimates included
lost profits associated with morbidity and mortality as well
Table 3 Average age of death from prostate cancer
2002 2005 2008 2011 Future estimates
2014 2017 2020
Average age of death (years) Fixed model 79.9 80.4 80.7
77.9 78.3 78.8 79.3 Linear model 80.2 80.8 81.3
Logarithmic model 80.3 80.7 81.1
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as the health-care costs of prostate cancer using the Vital
Statistics and the Patient Survey. That study’s findings
were rudimentary since no time-trend analysis and future
projection was performed.
Based on predictions from the National Cancer Center,
it is estimated that deaths from prostate cancer in Japan
will amount to 14,700 per year for 2020–2024 [15]. In
this study, we estimated that the number of deaths from
prostate cancer in 2020 would be 14,833 (fixed model)
and 15,597 (logarithmic model).
The present study is not free of limitations. First,
we used data obtained over a relatively short period
(1996–2008) to predict health-related indicators; thus,
caution should be applied when interpreting the re-
sults. For example, we estimated that the average age
of death would continue to rise, reaching around
81 years in 2020. Such a prediction may be too high.
The appropriateness of setting a minimum value
should also be examined. The average length of stay
for prostate cancer patients shortened drastically from
38.0 days in 1996 to 10.1 days in 2011; this occurred
following health-care reforms, which included a
change in the reimbursement scheme for hospitals. In
this study, we set the minimum value for an average
length of hospital stay at 8.1 days, which reflected the
average value for OECD countries. Because the aver-
age length of stay may become shorter in the future,
it is unclear whether or not this minimum value is
appropriate. When interpreting future COI estima-
tions for prostate cancer, these methodological limita-
tions should be considered.
Second, this study has limitations related to data avail-
ability. Because we lacked data about alternative treat-
ments, we assumed that all the hospitalized patients
underwent surgery. Medical expenses could vary with
endocrine and radiation therapies. The Ministry of Health,
Labour and Welfare allows researchers to use nationwide
claims data on public medical insurance; however, there
are limits on the accessible years of inpatient data, and no
representative cost data were available for our study.
Our estimation has no standard errors or confidence in-
tervals. However, our study attempted multiple approaches.
Table 4 Results of estimated COI of prostate cancer (billion yen)
2002 2005 2008 2011 Future estimates
2014 2017 2020
Direct cost 97.0 164.2 195.9 219.4 Fixed model 240.4 250.6 268.1
Linear model 256.5 292.7 336.2
Logarithmic model 239.7 248.0 258.6
Mixed model 256.5 292.7 336.2
Inpatient care 66.3 96.1 115.4 118.0 Fixed model 130.2 139.0 146.3
Linear model 118.8 135.1 153.6
Logarithmic model 127.3 127.0 125.5
Mixed model 118.8 135.1 153.6
Outpatient care 30.7 68.1 80.5 101.4 Fixed model 110.2 111.6 121.9
Linear model 137.7 157.6 182.6
Logarithmic model 112.4 121.4 133.1
Mixed model 137.7 157.6 182.6
Mortality cost 66.9 65.8 72.7 70.0 Fixed model 95.6 100.9 104.9
Linear model 96.6 100.2 105.9
Logarithmic model 94.9 100.9 103.6
Mixed model 79.5 81.6 83.6
Morbidity cost 10.7 16.9 17.5 17.9 Fixed model 18.7 19.4 19.4
Linear model 25.2 28.2 31.9
Logarithmic model 21.2 21.9 23.0
Mixed model 26.0 28.7 32.1
COI 174.5 246.9 286.0 307.3 Fixed model 354.7 370.9 392.4
Linear model 378.3 421.0 474.1
Logarithmic model 355.8 370.8 385.3
Mixed model 362.0 403.0 451.9
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The fixed model could be regarded as a reference because
it was the simplest estimation. The logarithmic model is
the low-end (in 2017, 2020), and the linear model is the
high-end estimation. This range of estimation would com-
plement standard errors or confidence intervals.
One of the purposes of predicting the future COI is to
provide basic information in allocating limited resources.
In Canada, the government has calculated the COI of
major diseases and used the findings to update its
health-care policy [16]. Predicting the future COI of
major diseases could similarly help in prioritizing and
determining health-care policy in Japan.
Conclusions
The results of this study suggest that the COI of prostate
cancer in Japan has been increasing and will maintain
this rise in the future. DC accounts for the largest pro-
portion of COI and is expected to continue increasing;
this will result in a further burden on public funds in
Japan, which has a universal public insurance system.
These trends are different from those observed with
other cancers. When evaluating the allocation of re-
sources for cancer control, it is necessary to consider
differences in the characteristics of the forms of cancer.
Abbreviations
COI: Cost of illness; DC: Direct cost; HC: Hospitalization cost; IC: Indirect cost;
iCd: Inpatient cost per day; LVd: 1-day labour value per person; LVl: Lifetime
labour value per person; MbC: Morbidity cost; MbCi: Morbidity cost of
inpatients; MbCo: Morbidity cost of outpatients; MtC: Mortality cost;
NDy: Number of deaths; OC: Outpatient cost; oCd: Outpatient cost per day;
THD: Total person-days of hospitalization; TOVy: Total person-days of
outpatient visits.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TK participated in the design of the study, performed the data collection and
analysis, and drafted the manuscript. KM participated in the design of the
study and performed the analysis. SF, KS, and SH performed the data
collection and analysis. TH conceived the study, participated in its design,





This study was supported in part by the Japan Society for the Promotion of
Science KAKENHI Grant No. 24790520.
Author details
1Department of Social Medicine, Toho University School of Medicine,
5-21-16, Omori-nishi, Ota-ku 143-8540 Tokyo, Japan. 2Chiba Psychiatric
Medical Center, Chiba, Japan.
Received: 22 December 2014 Accepted: 22 September 2015
References
1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for
27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al.
International variation in prostate cancer incidence and mortality rates. Eur
Urol. 2012;61:1079–92.
3. Ministry of Health, Labour and Welfare: Patient Survey. http://www.mhlw.
go.jp/toukei/list/10-20.html. Accessed 10 Jul. 2016.
4. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The
worldwide epidemiology of prostate cancer: perspectives from autopsy
studies. Can J Urol. 2008;15:3866–71.
5. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. The economic
burden of prostate cancer, California, 1998. Cancer. 2002;94:2906–13.
6. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int.
2011;108:806–13.
7. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The
economic burden of prostate cancer in Canada: forecasts from the Montreal
Prostate Cancer Model. CMAJ. 2000;162:987–92.
8. Grover SA, Zowall H, Coupal L, Krahn MD. Prostate cancer: 12. The
economic burden. CMAJ. 1999;160:685–90.
9. Koinuma N, Ogata T. Cost of cancer of Japan. J Jpn Soc Healthcare
Administration. 2008;45(Suppl:68). (in Japanese).
10. Rice DP. Estimating the cost of illness. Am J Public Health Nations Health.
1967;57:424–40.
11. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a
replication and update. Health Care Financ Rev. 1985;7:61–80.
12. Matsumoto K, Haga K, Hanaoka S, Kitazawa T, Hasegawa T. Cost of illness for
major cancers in Japan. J Jpn Soc Health Care Manage. 2012;13:2–6
(in Japanese).
13. Haga K, Matsumoto K, Kitazawa T, Seto K, Fujita S, Hasegawa T. Cost of
illness of the stomach cancer in Japan - a time trend and future projections.
BMC Health Serv Res. 2013;doi:10.1186/1472-6963-13-283.
14. Ministry of Education, Culture, Sports, Science and Technology and Ministry
of Health, Labour and Welfare. Ethical guidelines for epidemiological
research. 2008. http://www.lifescience.mext.go.jp/files/pdf/n796_01.pdf.
Accessed 10 Jul. 2016.
15. Sobue T. Gan tōkei hakusho 2012. Tokyo: shinoharashinsha; 2012
(in Japanese).
16. Public Health Agency of Canada. Economic Burden of Illness in Canada.
2005–2008. http://www.phac-aspc.gc.ca/publicat/ebic-femc/2005-2008/
assets/pdf/ebic-femc-2005-2008-eng.pdf. Accessed 10 Jul. 2016.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kitazawa et al. BMC Health Services Research  (2015) 15:453 Page 7 of 7
